

**Amendments to the Specification:**


**Page 1, after the title, insert the following paragraph:**

This Application is the National Phase of International Application No. PCT/JP2004/010352 filed July 14, 2004, which designated the U.S. and was not published under PCT Article 21(2) in English, and this application claims, via the aforesaid International Application, the foreign priority benefit of and claims the priority from Japanese Application No. 2003-274886, filed July 15, 2003, the complete disclosures of which are incorporated herein by reference.

**Please amend the third paragraph on page 2, ending on page 4 as follows:**


Item 1 An anti-coronavirus agent comprising as an active ingredient a compound represented by formula (1):

Formula (1)




wherein R<sup>1</sup> represents formula (2) or (3) below:

Formula (2)



wherein Y is S, O or NH; each R<sup>3</sup> is independently a C<sub>1</sub>-C<sub>4</sub> alkyl group, C<sub>1</sub>-C<sub>4</sub> alkoxy group, C<sub>1</sub>-C<sub>4</sub> alkylamino group, amido group, carboxy group, amino group, hydroxy group, or halogen atom; m is 0 or 1, and p is an integer from 0 to 5

Formula (3)




wherein Y, R<sup>3</sup> and m are as above; ~~p is 0 or 1~~, and r is an integer from 0 to 6;

each R<sup>2</sup> is independently a C<sub>1</sub>-C<sub>4</sub> alkyl group, C<sub>1</sub>-C<sub>4</sub> alkoxy group, C<sub>1</sub>-C<sub>4</sub> alkylamino group, amido group, carboxy group, amino group, hydroxy group, halogen atom; and n is an integer from 0 to 3;

or a pharmaceutically acceptable salt thereof.


**Please amend the paragraph bridging pages 6 and 7 as follows:**

The anti-coronavirus agent of the present invention comprises as an active ingredient a compound represented by formula (1):




wherein R<sup>1</sup> represents formula (2) or (3) below:

Formula (2)



wherein Y is S, O or NH; each R<sup>3</sup> is independently a C<sub>1</sub>-C<sub>4</sub> alkyl group, C<sub>1</sub>-C<sub>4</sub> alkoxy group, C<sub>1</sub>-C<sub>4</sub> alkylamino group, amido group, carboxy group, amino group, hydroxy group, or halogen atom; m is 0 or 1, and p is an integer from 0 to 5

Formula (3)



wherein Y, R<sup>3</sup> and m are as above; ~~p is 0 or 1~~, and r is an integer from 0 to 6;  
each R<sup>2</sup> is independently a C<sub>1</sub>-C<sub>4</sub> alkyl group, C<sub>1</sub>-C<sub>4</sub> alkoxy group, C<sub>1</sub>-C<sub>4</sub> alkylamino group, amido group, carboxy group, amino group, hydroxy group, or halogen atom; and  
n is an integer from 0 to 3;

or a pharmaceutically acceptable salt thereof.

**Please amend the first full paragraph on page 8 as follows:**

A more preferable example of R<sup>1</sup> is represented by the following formula (6):

